News Sanofi Nasdaq

Equities

GCVRZ

US80105N1138

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.18%	+1.27%

06-27	CAC40: caution prevails ahead of crucial deadlines	CF
06-27	CAC40: consolidates solo, OAT/Bund spread widens to 81Pb	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CAC40: caution prevails ahead of crucial deadlines	06-27	CF
CAC40: consolidates solo, OAT/Bund spread widens to 81Pb	06-27	CF
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	06-27	MT
Sanofi - Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM	06-27	AQ
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data	06-27	MT
Top Premarket Gainers	06-27	MT
Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment	06-27	DJ
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study	06-27	MT
CAC40: below 7600 pts, held back by the automotive sector	06-27	CF
Vigil Neuroscience Receives $40 Million Investment From Sanofi	06-27	MT
The same old winners	06-27
Sanofi: positive publication for Dupixent in NEJM	06-27	CF
Sanofi Partakes in Formation Bio's $372 Million Fundraising	06-27	MT
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM	06-26	GL
Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine	06-26	CI
FDA approves Verona Pharma's therapy for 'smoker's lungs'	06-26	RE
Sanofi-backed Drug Developer Formation Bio Raises $372 Million	06-26	MT
Sanofi-backed Formation Bio raises $372 million in late-stage funding round	06-26	RE
Euroapi: updated outlook for 2024	06-26	CF
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	06-26	MT